Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3-acids Ethylesters 90 in Type Ⅱb Hyperlipidemia

March 19, 2014 updated by: Kuhnil Pharmaceutical Co., Ltd.

Efficacy and Safety of Co-administration of Omacor Plus Atorvastatin Compared With Atorvastatin Monotherapy in Patients With Type Ⅱb Dyslipidemia: a Multicenter, Double-blind, Randomized, Active-controlled, Parallel, Phase Ⅲ Study

The purpose of this study is to evaluate the efficacy and safety of combination therapy of omega-3-acids ethylesters 90/Atorvastatin calcium in type Ⅱb hyperlipidemia

Study Overview

Study Type

Interventional

Enrollment (Anticipated)

80

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Anyang, Gyeonggi, Korea, Republic of, 431-070
        • Active, not recruiting
        • Hallym University Sacred Heart Hospital
      • Incheon, Korea, Republic of, 405-760
        • Not yet recruiting
        • Gachon University Gil Hospital
      • Seoul, Korea, Republic of, 152-703
        • Recruiting
        • Korea University Guro Hospital
      • Uijongbu, Gyeonggi, Korea, Republic of, 480-717
        • Active, not recruiting
        • Uijongbu St. Mary's Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • LDL≥160mg/dl, 200mg/dl≤TG<500mg/dl
  • In the case of smokers, he agrees should be smoke-free
  • In the case of women of childbearing age, urine pregnancy test must be negative

Exclusion Criteria:

  • Patients with acute artery disease within 3 months
  • History of revascularization procedure or aneurism operation within 6months
  • Patients with myopathy, rhabdomyolysis
  • Patients with pancreatitis
  • Patients with HIV positive
  • History of malignant tumor within 2 years
  • Patients must be treated with medications prohibited for concomitant use during study period
  • Patients with uncontrolled hypertension(SBP>180mmHg or DBP>110mmHg)
  • Serum Creatinine>1.2mg/dl(female), >1.4mg/dl(male)
  • AST or ALT > 2X ULN
  • CPK > 2X ULN
  • Patients with galactose intolerance or Lapp lactase deficiency, glucose-galactose malabsorption
  • Allergy or Hypersensitive to investigational drug
  • History of drug or alcohol abuse within 2 years
  • In the case of smokers, who do not intend to non smoking
  • Women with pregnant, breast-feeding
  • Patients treated with any investigational drugs within 1 month at the time consents are obtained
  • Not eligible to participate for the study at the discretion of investigator

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Atorvastatin 20mg, Omega-3-acids ethylesters 90 4g
Atorvastatin calcium 20mg, Omega-3-acids ethylesters 90 4g: po, q.d
Other Names:
  • Lipitor 20mg
Other Names:
  • Omacor Soft Capsule 4g
Placebo Comparator: Atorvastatin 20mg, Placebo
Atorvastatin calcium 20mg, Placebo for Omega-3-acids ethylesters 90 4g: po, q.d
Other Names:
  • Lipitor 20mg

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
The mean percent change of Triglyceride(TG)
Time Frame: from baseline at week 8
from baseline at week 8

Secondary Outcome Measures

Outcome Measure
Time Frame
The mean percent change of Triglyceride(TG)
Time Frame: from baseline at week 4
from baseline at week 4
The mean percent change of Total Cholesterol(TC), LDL-C, HDL-C
Time Frame: from baseline at week 4,8
from baseline at week 4,8

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Hong Seog Seo, Ph.D., Korea University Guro Hospital
  • Principal Investigator: Hee Kyoung Cheon, Ph.D., Uijongbu St. Mary's Hospital
  • Principal Investigator: Sang-Ho Jo, Ph.d., Hallym University Medical Center
  • Principal Investigator: Mi-Seung Shin, Ph.D, Gachon University Gil Medical Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2014

Primary Completion (Anticipated)

October 1, 2014

Study Completion (Anticipated)

December 1, 2014

Study Registration Dates

First Submitted

January 10, 2014

First Submitted That Met QC Criteria

January 10, 2014

First Posted (Estimate)

January 14, 2014

Study Record Updates

Last Update Posted (Estimate)

March 20, 2014

Last Update Submitted That Met QC Criteria

March 19, 2014

Last Verified

March 1, 2014

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe